Compare GXO Logistics Inc (GXO) vs TG Therapeutics Inc (TGTX) Price & Performance

GXO trades at $46.56, up 1.24% today, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.59, beating estimates, and maintains strong analyst support with an 88.89% buy rating. Recent news highlights strategic partnerships with Columbia Sportswear and expansion in aerospace & defense, signaling growth initiatives. Revenue for 2025 was $13.18 billion, with a net income margin of 0.96%, though profitability remains modest.

The outlook is positive, driven by analyst consensus price target of $66.67 and improving industry prospects. Key opportunities include operational efficiency gains from new labor management systems and sector tailwinds. Risks involve stagnant margins and competitive pressures, requiring close monitoring of execution on growth targets to justify current valuations.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.